Bildkälla: Stockfoto

Cantargia Q3 2024: IL1RAP Companion Diagnostic Next - Redeye

Redeye comments on Cantargia’s Q3 report, the proposed rights issue of SEK170m and the plans to focus on IL1RAP-high patients.

Redeye comments on Cantargia’s Q3 report, the proposed rights issue of SEK170m and the plans to focus on IL1RAP-high patients.
Börsvärldens nyhetsbrev
ANNONSER